Seer (SEER) Proxy filing summary

Executive summary

• Annual Meeting scheduled for July 28, 2026, with a critical vote on the composition of the Board of Directors.

• Board urges stockholders to vote for the seven incumbent nominees to maintain strategic direction in proteomics.

• Communication emphasizes the Board's expertise and alignment with long-term value creation.

• Forward-looking statements highlight ongoing strategies, R&D initiatives, and business objectives.

Voting matters and shareholder proposals

• Stockholders are asked to vote on the election of seven director nominees using the BLUE proxy card.

• A proxy contest is underway, with Bradley Radoff and Michael Torok seeking to replace three incumbent directors.

• Board opposes the dissident nominees, citing lack of relevant experience and potential misalignment with shareholder interests.

Board of directors and corporate governance

• Incumbent nominees include Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Dipchand Nishar, Isaac Ro, and Nicolas Roelofs.

• Board highlights the critical expertise of the three directors targeted for removal, including deep proteomics, life sciences, and capital markets experience.

• Board unanimously determined dissident nominees lack necessary skills and independence for effective governance.

• Board offered to interview dissident nominees, but the offer was declined.